Sun Pharma projects high single-digit revenue growth for FY25, with R&D investments at 8-10% of sales and focus on US product launches and global specialty business.
Sun Pharmaceutical Industries, India's leading drugmaker, projects a high single-digit growth in top line revenue for FY25. The company reported a consolidated total revenue of Rs 48,497 crore for FY24. MD Dilip Shanghvi highlighted that R&D investments will be 8-10% of sales this year as the firm focuses on product launches in the US and ramping up its global specialty business.
June 02, 2024
3 Articles